





## **cobas® eplex** respiratory pathogen panel 2

Fast, comprehensive results can help differentiate between SARS-CoV-2, influenza, RSV and other common respiratory pathogens



The clinical presentation of respiratory pathogens is similar, complicating diagnosis and therapy selection. Fast, accurate results are critical, especially in high risk patients.



## **Respiratory infections**



Clinical impact of rapid comprehensive molecular testing

cause more doctor visits and absences from school and work than any other illness.<sup>1</sup>



# 17.2 billion

cases of upper respiratory infections globally in 2019<sup>2</sup>



## Adults average upper respiratory infections annually<sup>3</sup>



## Children get 10 colds

per year<sup>1</sup>

# 8.4%

Reduction in emergency department admissions with a positive **cobas**<sup>®</sup> **eplex** system result<sup>5</sup>



Quickly identify patients with co-infections at higher risk of severe disease<sup>6</sup>

41%

of antibiotic prescriptions for respiratory infections were inappropriate<sup>7</sup>



## Severe respiratory infections can lead to hospitalisation or death

While most infections are mild. complications such as pneumonia or sepsis can occur.4

### Who should be tested?

- All inpatients with respiratory symptoms
- Emergency department patients with respiratory symptoms
- Any person at risk for complications

### People at high risk for complications<sup>8-10</sup>



Pregnant

women





Children < 2 and adults 65+



Anyone with a compromised immune system

### Medical conditions that increase risk

- Stroke
  - Asthma
- Diabetes
- Weakened immune system
- Blood, lung, heart, kidney
- and liver disease

Sample-to-answer, comprehensive respiratory tests provide rapid and accurate results that can improve laboratory efficiency and patient care.





Automatically email customised reports to staff to monitor pathogen circulation and infection rates in your hospital Multiplex respiratory testing can contribute to a **successful antimicrobial stewardship** program<sup>5</sup>

#### Comprehensive coverage of the most common respiratory pathogens<sup>11</sup>

Viral targets			Bacterial targets
Adenovirus	Human Bocavirus	Influenza B	Bordetella pertussis
Coronavirus 229E	Human Metapneumovirus	Parainfluenza 1	Legionella pneumophila
Coronavirus HKU1	Human Rhinovirus/Enterovirus	Parainfluenza 2	Mycoplasma pneumoniae
Coronavirus NL63	Influenza A	Parainfluenza 3	
Coronavirus OC43	Influenza A H1	Parainfluenza 4	
SARS-CoV-2	Influenza A H1-2009	Respiratory Syncytial Virus A	
MERS-CoV	Influenza A H3	Respiratory Syncytial Virus B	

#### cobas eplex respiratory pathogen panel<sup>2</sup>

Key parameters	Description
Platform	cobas* eplex system
Sample type	Nasopharyngeal swab (NPS)
Sample volume	200 µL
Test duration	~90 minutes
Kit size	12 tests

#### **Ordering information**

Kit description	Material number
cobas eplex respiratory pathogen panel 2 CE-IVD	09556486001

#### References

- <sup>1</sup> Upper Respiratory Infection (URI or Common Cold). https://www.hopkinsmedicine. org/health/conditions-and-diseases/upper-respiratory-infection-uri-or-commoncold#:~:text=What%20is%20the%20common%20cold,work%20than%20any%20 other%20illness. Date accessed March 2024.
- <sup>2</sup> Jin X, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021 Jun 28;37:100986. doi:10.1016/j.eclinm.2021.100986. PMID: 34386754; PMCID: PMC8343248.
- <sup>3</sup> Johns Hopkins Medicine ABX Guide reference https://www.hopkinsguides.com/hopkins/ view/Johns\_Hopkins\_ABX\_Guide/540570/all/Upper\_Respiratory\_Infections?q=uri. Date accessed: December 2023.
- <sup>4</sup> Flu Symptoms & Complications. Centers for Disease Control and Prevention. https:// www.cdc.gov/flu/symptoms/symptoms.htm. Date accessed: December 2023.
- <sup>5</sup> Weiss Z, et al. Opportunities Revealed for Antimicrobial Stewardship and Clinical Practice with Implementation of a Rapid Respiratory Multiplex Assay. J Clin Microbiol.

COBAS and EPLEX are trademarks of Roche. ©2024 F. Hoffmann-La Roche Ltd For *In Vitro* Diagnostic Use. (Outside the U.S.) MC--08322

#### diagnostics.roche.com/eplex

- <sup>6</sup> Hanson K, et al. Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA's Diagnostics Committee. Clin Infect Dis. 2020 Dec 17;71(10):2744-2751. doi: 10.1093/cid/ciaa508.
- <sup>7</sup> Havers FP, et. al. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018;1(2):e180243. doi:10.1001/ jamanetworkopen.2018.0243.
- <sup>8</sup> People at high risk for severe RSV infection. Centers for Disease Control and Prevention. https://www.cdc.gov/rsv/high-risk/index.html. Date accessed: December 2023.
- People at high risk for flu complications. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/highrisk/index.htm. Date accessed: December 2023.
- <sup>10</sup> People with Certain Medical Conditions. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/your-health/understanding-risk.html. Date accessed: December 2023.
- <sup>11</sup> cobas eplex respiratory pathogen panel 2 (RP2) Method Sheet, CE-IVD (10300418001).